Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer

American Journal of Therapeutics

Volumn 17, Issue 2, 2010, Pages 148-158

  Nurgalieva, Zhannat ^a   Xia, Rui ^a   Liu, Chih Chin ^a   Burau, Keith ^a   Hardy, Dale ^a   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Breast cancer; Chemotherapy; Lung cancer; Ovarian cancer; Peripheral neuropathy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

AGED; ARTICLE; BREAST CALCIFICATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG MONITORING; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; OVARIAN NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; PLATINUM COMPOUNDS; RISK FACTORS; SEER PROGRAM; TAXOIDS;

EID: 77949975990     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181a3e50b     Document Type: Article

References (40)

1. Abraham J, Allegra CJ. Bethesda Handbook of Clinical Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
2. Baquiran DC. Lippincott,s Cancer Chemotherapy Handbook. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
3. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with preexisting neuropathy. Neurology. 2003;60:337-340.
4. Malik B, Stillman M. Chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2008;8:56-65.
5. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9-17.
6. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol. 2006;24: 1633-1642.
7. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27-46.
8. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20: 719-725.
9. Dougherty PM, Cata JP, Cordella JV, et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004;109:132-142.
10. Rowinsky EK, Chaudhry V, Cornblath DR, et al. Neurotoxicity of taxol. J Natl Cancer Inst Monogr. 1993;15: 107-115.
11. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004;22:2061-2068.
12. Henderson CI, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
13. Mamounas EP, Bryant J, Lembersk B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686-3696.
14. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
15. du Bois A, Luck HJ, MeierW, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-1329.
16. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682-1691.
17. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
18. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597.
19. Douillard J, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719-727.
20. National Cancer Institute. SEER program: overview. Surveillance Research program. Available at: http://seer. cancer.gov/about/. Accessed May 20, 2008.
21. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):3-18.
22. U.S. Public Health Services. International Classification of Diseases, 9th Revision, Clinical Modification. 5th ed. Los Angeles, CA: Practice Management Information Corporation; 1996.
23. American Medical Association. Physicians, Current Procedural Terminology: CPT 94. Chicago, IL: American Medical Association; 1993.
24. Health Care Financing Administration. HCFA Common Procedure Coding System (HCPCS): National Level II Medicare Codes. Los Angeles, CA: Practice Management Information Corporation; 1994.
25. Du XL, Fang S, Meyer TE. Impact of treatment and socioeconomic status on racial disparities in survival among older women with breast cancer. Am J Clin Oncol. 2008;31:125-132.
26. Hilkens PH, Pronk LC, Verweij J, et al. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer. 1997;75: 417-422.
27. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006;42:24-30.
28. Goetz MP, Erlichman C,Windebank AJ, et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003;21: 3761-3769.
29. Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994;35:304-311.
30. Verstappen CCP, Postma TJ, Hoekman K, et al. Peripheral neuropathy due to therapy with paclitaxel, gemcitabine and cisplatin in patients with advanced ovarian cancer. J Neuroonocol. 2003;63:201-205.
31. Bacon M, James K, Zee B. A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC). Int J Gynecol Cancer. 2003;13:428-434.
32. Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2004;15:1517-1526.
33. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology. 1989;39: 368-373.
34. Hilkens PHE, Verweij J, Vecht ChJ, et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Onocol. 1997;8:1-4.
35. Fossella FV, Lee JS, Murohy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994;12:1238-1244.
36. Akerley W, Herndon JE, Egorin MJ, et al. Weekly, highdose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003;97:2480-2486.
37. Mielke S, Mross K, Gerds TA, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs. 2003;14:785-792.
38. Gogas H, Shapiro F, Aghajanian C, et al. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol. 1996;61:22-26.
39. Park SB, Krishnan AV, Lin CS, et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15:3081-3094.
40. Walker M, Ni O. Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol. 2007;30:82-92.